
Opinion|Videos|June 5, 2025
Clinical Nurse Educators, Dosing Titrations to Manage Parkinson Disease
Panelists discuss how clinical nurse educators serve as vital partners in continuous subcutaneous apomorphine infusion management, providing patient education, troubleshooting technical issues, and collaborating with physicians on dosing titrations to optimize Parkinson disease symptom control.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Role of Clinical Nurse Educators
Clinical Nurse Educator Roles:
- Initial patient assessment and education
- Device training and ongoing support
- Regular monitoring and titration recommendations
- First point of contact for troubleshooting
- Liaison between patient and physician
- Coordination of multidisciplinary care
Assistance With Dosing Titrations:
- Systematic assessment of response using standardized tools
- Remote monitoring and telehealth support
- Implementation of physician-directed titration protocols
- Identification of adverse effects requiring intervention
- Documentation and communication of patient response patterns
- Proactive management of common adverse effects
- Guidance on infusion site rotation and care
- Regular follow-up to ensure optimal adjustment
Advertisement
Related to this article

A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.

The director of the Center for Neurological Restoration at Cleveland Clinic discusses when to transition beyond oral medication and considerations for selecting device-aided therapies in PD.

The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.

A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral hemorrhage reduced recurrent stroke risk.

A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.

Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Clene Submits NDA Seeking Accelerated Approval for ALS Drug
2
Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated
3
Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis
4
FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia
5

